Skip to main content

Table 3 Associations of TGFBR2 and IL12B SNPs with overall survival in discovery and replication samples

From: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

Breast cancer patients

TGFBR2 rs1367610 (G > C)

IL12B rs2546892 (G > A )

IL12B rs2853694 (A > C)

Cases, number

Events, number

HR (95% CI)

P -value

Cases, number

Events, number

HR (95% CI)

P -value

Cases, number

Events, number

HR (95% CI)

P -value

Discovery

            

ER-negative and received chemotherapya

1499

267

1.54 (1.22, 1.95)

3.08 × 10−4

1499

267

1.50 (1.21, 1.86)

1.81 × 10−4

1499

267

0.73 (0.61, 0.87)

3.67 × 10−4

 

I 2c = 86.7%; P heterogeneityd = 5.00 × 10−4

I 2c = 78.5%; P heterogeneityd = 9.50 × 10−3

I 2c = 75.9%; P heterogeneityd = 0.016

Replication

            

ER-negative and received chemotherapy

            

 BCAC Asian studiesa

372

42

2.18 (0.85, 5.60)

0.105

372

42

0.62 (0.30, 1.26)

0.187

372

42

1.03 (0.63, 1.67)

0.919

 POSH studyb

127

62

1.59 (0.94, 2.69)

0.084

127

62

1.09 (0.67, 1.78)

0.715

127

62

0.87 (0.62, 1.22)

0.408

Combined replication

            

ER-negative and received chemotherapy

499

104

1.71 (1.08, 2.72)

0.022

499

104

0.91 (0.61, 1.36)

0.659

499

104

0.92 (0.69, 1.21)

0.535

 

I 2c = 0%; p heterogeneityd = 0.567

I 2c = 40.4%; P heterogeneityd = 0.20

I 2c = 0%; P heterogeneityd = 0.577

Combined overall

            

ER-negative received adjuvant chemotherapy

1998

371

1.57 (1.28, 1.94)

2.05 × 10−5

1998

371

1.11 (0.70, 1.76)

0.653

1998

371

0.78 (0.67, 0.90)

8.00 × 10−4

 

I 2c = 0%; P heterogeneityd = 0.781

I 2c = 68.3%; P heterogeneityd = 0.04

I 2c = 6.4%; P heterogeneityd = 0.344

  1. aHR adjusted for age of diagnosis, tumor size, tumor grade, node status and principal components to account for population substructure and stratified by study. bHR adjusted for age of diagnosis, tumor size, tumor grade, node status and metastasis status. c I 2 index derived on the basis of effect estimate and variance in each study. d P-value for test of heterogeneity between studies using the DerSimonian-Laird test. TGFBR2, transforming growth factor, beta receptor II; SNP, single nucleotide polymorphism; HR, hazard ratio; ER, estrogen receptor; BCAC, Breast Cancer Association Consortium; IL12B, interleukin 12B; CI, confidence interval; and POSH, Prospective Study of Outcomes in Sporadic versus Hereditary Breast Cancer.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us